Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

32 Publicaciones científicas disponibles

  • Tolerogenic dendritic cell-based treatment for multiple sclerosis

    9 de septiembre de 2019 | Revista: BMJ Open

    Willekens B# (1,2), Presas-Rodríguez S# (3,4), Mansilla MJ (5,6), Derdelinckx J (1,2), Lee WP (7), Nijs G (7), De Laere M (2), Wens I (2), Cras P (1), Parizel P (8), Van Hecke W (9), Ribbens A (9), Billiet T (9), Adams G (10), Couttenye MM 11, Navarro-Barriuso J (5,6), Teniente-Serra A (5,6), Quirant-Sánchez B (5,6), Lopez-Diaz de Cerio A (12,13), Inogés S (12,13), Prosper F (12,14), Kip A (15), Verheij H (15), Gross CC (16,17), Wiendl H (16,17), Van Ham MS (18,19), Ten Brinke A (18,19), Barriocanal AM (20,21), Massuet-Vilamajó A (22), Hens N (23,24), Berneman Z (2,7), Martínez-Cáceres E (5), Cools N# (25,7), Ramo-Tello C# (26); RESTORE consortium.

    (1) Department of Neurology, University Hospital Antwerp, Edegem, Belgium.
    (2) Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium.
    (3) Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    (4) Department of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.
    (5) Division of Immunology, LCMN, Hospital Universitario Germans Trias i Pujol and Research Institute, Badalona, Spain.
    (6) Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
    (7) Center for Cell Therapy and Regenerative Medicine, University Hospital Antwerp, Edegem, Belgium.
    (8) Department of Radiology, University Hospital Antwerp, Edegem, Belgium.
    (9) Icometrix NV, Leuven, Belgium.
    (10) C-Clear Partners, Mortsel, Belgium.
    (11) Department of Nephrology, University Hospital Antwerp, Edegem, Belgium.
    (12) Haematology-Cell Therapy Area, clinica universidad de navarra, Pamplona, Spain.
    (13) Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (14) Program of Haematology-Oncology, CIMA, Universidad de Navarra, Pamplona, Spain.
    (15) Lygature, Utrecht, The Netherlands.
    (16) Department of Neurology, University Hospital Munster, Munster, Germany.
    (17) Department of Neurology, University of Munster, Munster, Germany.
    (18) Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
    (19) Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    (20) Clinical Research Polyvalent Unit, Clinial Trial Unit-Spanish Clinical Research Network, Germans Trias i Pujol Health Sciences Research Institute, Badalona, Spain.
    (21) Department of Pharmacology, Therapeutic and Toxicology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
    (22) Institut de Diagnòstic per la Imatge, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    (23) Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Universiteit Hasselt, Hasselt, Belgium.
    (24) Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine & Infectious Disease Institute (VAXINFECTIO) & Center for Statistics, University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium.
    (25) Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium
    (26) Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    # Contributed equally


  • Adoptive T-cell therapy with CD45RA-deplected donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients

    26 de marzo de 2019 | Revista: Antiviral Therapy

    Yuste JR (1,2), Díaz de Cerio AL (3,4), Rifón J (4), Moreno C (3), Panizo M (1), Inogés S (3,4).

    (1) Division of Infectious Diseases, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Department of Internal Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Immunology and Immuotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Hematology Service and Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.


  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    12 de mayo de 2017 | Revista: Journal of Transational Medicine

    Inogés S (1,2), Tejada S (3), de Cerio AL (4,5), Pérez-Larraya JG (6), Espinós J (7), Idoate MA (8), Domínguez PD (9), de Eulate RG (9), Aristu J (10), Bendandi M (11,12), Pastor F (13), Alonso M (14), Andreu E (5), Cardoso FP (4,15), Valle RD (16). (1) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (2) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (3) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (4) Cell Therapy Area, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (5) Immunology and Immunotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (6) Neurology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (7) Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (8) Pathology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (9) Radiology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (10) Radiation Oncology Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (11) Section on Hematology/Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Wake Forest University Baptist Healthcare Center, Winston-Salem, NC, USA.
    (12) Section of Hematology/Oncology, Department of Internal Medicine, W.G Hefner VA Medical Center, Salisbury/Charlotte, NC, USA.
    (13) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (14) Program in Solid Tumors and Biomarkers, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Avenida Pio XII 55, 31008, Pamplona, Navarra, Spain.
    (15) Haematology and Haemotherapy Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain.
    (16) Neurosurgery Department, Clínica Universidad de Navarra, Avenida Pio XII 36, 31008, Pamplona, Navarra, Spain


  • MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells

    2 de abril de 2016 | Revista: Oncotarget

    Soldevilla MM (1,2), Villanueva H (1,2), Casares N (2,3), Lasarte JJ (2,3), Bendandi M (4), Inoges S (2,5), López-Díaz de Cerio A (2,5), Pastor F (1,2).

    (1) Program of Molecular Therapies, Aptamer Unit, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
    (2) Instituto de Investigación Sanitaria de Navarra (IDISNA), Recinto de Complejo Hospitalario de Navarra, Irunlarrea, Pamplona, Spain.
    (3) Program Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
    (4) Ross University School of Medicine, Roseau, Portsmouth, Commonwealth of Dominica.
    (5) Clínica Universidad de Navarra, Pamplona, Spain.

No hay más publicaciones científicas

No hay más páginas para cargar